
        <!DOCTYPE html>
        <html>
        <head>
            <title>Lecanemab PET Analysis Report</title>
            <style>
                body { font-family: Arial, sans-serif; margin: 20px; }
                h1, h2, h3 { color: #2c3e50; }
                .report-header { background-color: #f8f9fa; padding: 20px; border-radius: 5px; margin-bottom: 20px; }
                .section { margin-bottom: 30px; }
                .img-container { margin: 10px 0; text-align: center; }
                .img-container img { max-width: 100%; border: 1px solid #ddd; border-radius: 5px; }
                table { border-collapse: collapse; width: 100%; margin: 20px 0; }
                th, td { text-align: left; padding: 12px; border-bottom: 1px solid #ddd; }
                th { background-color: #f2f2f2; }
                tr:hover { background-color: #f5f5f5; }
                .positive-change { color: green; }
                .negative-change { color: red; }
            </style>
        </head>
        <body>
            <div class="report-header">
                <h1>Lecanemab PET Analysis Report</h1>
                <h2>Condition: Normal</h2>
                <p>Date: 2025-03-06 01:12:53</p>
            </div>
            
            <div class="section">
                <h2>Summary of Findings</h2>
                <p>This report presents PET imaging analysis evaluating the effect of Lecanemab in a subject with Normal condition.</p>
        
                <p><strong>Overall Drug Efficacy Score:</strong> 0.01</p>
            
                <h3>Pathway Effects:</h3>
                <ul>
                <li><strong>Amyloid:</strong> 0.01</li><li><strong>Tau:</strong> 0.01</li><li><strong>Apoptosis:</strong> 0.00</li><li><strong>Autophagy:</strong> 0.00</li><li><strong>Lipid:</strong> 0.00</li><li><strong>Synaptic:</strong> 0.00</li></ul>
                <table>
                    <tr>
                        <th>Biomarker</th>
                        <th>Mean Change</th>
                        <th>Interpretation</th>
                    </tr>
                    <tr>
                        <td>Amyloid PET SUVr</td>
                        <td class="positive-change">-5.0%</td>
                        <td>Reduction in amyloid burden</td>
                    </tr>
                    <tr>
                        <td>Tau PET SUVr</td>
                        <td class="positive-change">-3.0%</td>
                        <td>Reduction in tau pathology</td>
                    </tr>
                </table>
        
                <h3>Regional Changes</h3>
                <table>
                    <tr>
                        <th>Brain Region</th>
                        <th>Amyloid Change (%)</th>
                        <th>Tau Change (%)</th>
                    </tr>
        
                    <tr>
                        <td>Hippocampus</td>
                        <td class="positive-change">-6.5%</td>
                        <td class="positive-change">-3.9%</td>
                    </tr>
            
                    <tr>
                        <td>Entorhinal Cortex</td>
                        <td class="positive-change">-6.5%</td>
                        <td class="positive-change">-3.9%</td>
                    </tr>
            
                    <tr>
                        <td>Prefrontal Cortex</td>
                        <td class="positive-change">-5.5%</td>
                        <td class="positive-change">-3.3%</td>
                    </tr>
            
                    <tr>
                        <td>Temporal Lobe</td>
                        <td class="positive-change">-5.5%</td>
                        <td class="positive-change">-3.3%</td>
                    </tr>
            
                    <tr>
                        <td>Parietal Lobe</td>
                        <td class="positive-change">-4.5%</td>
                        <td class="positive-change">-2.7%</td>
                    </tr>
            
                    <tr>
                        <td>Posterior Cingulate</td>
                        <td class="positive-change">-4.5%</td>
                        <td class="positive-change">-2.7%</td>
                    </tr>
            
                    <tr>
                        <td>Precuneus</td>
                        <td class="positive-change">-4.5%</td>
                        <td class="positive-change">-2.7%</td>
                    </tr>
            
                </table>
            </div>
        
            <div class="section">
                <h2>Amyloid PET Analysis</h2>
        
                <h3>Amyloid PET Comparison</h3>
                <div class="img-container">
                    <img src="amyloid_comparison.png" alt="Amyloid PET Comparison">
                </div>
            
                <h3>Amyloid PET Difference Map</h3>
                <div class="img-container">
                    <img src="amyloid_difference_map.png" alt="Amyloid PET Difference Map">
                </div>
            
            </div>
        
            <div class="section">
                <h2>Tau PET Analysis</h2>
        
                <h3>Tau PET Comparison</h3>
                <div class="img-container">
                    <img src="tau_comparison.png" alt="Tau PET Comparison">
                </div>
            
                <h3>Tau PET Difference Map</h3>
                <div class="img-container">
                    <img src="tau_difference_map.png" alt="Tau PET Difference Map">
                </div>
            
            </div>
            
            <div class="section">
                <h2>Interpretation and Conclusion</h2>
        
                <p>Lecanemab shows mild effects on amyloid plaque burden, with some improvement in the distribution pattern.
                This suggests partial target engagement.</p>
                
                <p>The tau pathology shows similar modest improvement. While the magnitude of changes is not dramatic,
                any reduction in pathological protein burden could be clinically meaningful over longer treatment periods.</p>
            
                <p><strong>Clinical Significance:</strong> Reduction in amyloid and tau burden as measured by PET has been 
                associated with slower clinical progression in Alzheimer's disease. These imaging findings should be considered
                alongside clinical assessment of cognition and function.</p>
            </div>
        </body>
        </html>
        